In conjunction with the BRAVE Serbia International Combat Week, BRAVE Combat Federation has expanded its second visit to Belgrade to include a massive co-main event fight. Darko Stosic and Shamil Gaziev square off in the Heavyweights matchup at BRAVE CF 69 on February 18.
Bahrain's Shamil Gaziev is seeking to add the biggest victory of his career to his perfect professional record. He won the European, African, and Asian IMMAF championships in 2019 and took home a bronze medal at the World Championships, capping off an almost flawless amateur season.
He has continued to dominate competition since going pro, winning nine games in a row. Shamil recently made his BRAVE CF debut with a dominant second-round KO victory that garnered him a nomination for 2022 KO of The Year at the BRAVE CF End of Year awards.
Stosic, who has a professional record of 17 wins and 4 losses, is now the top-ranked heavyweight in the United States. He is also listed in the top three in the Eastern European and Polish rankings. He will rely on the support of his local crowd to beat Gaziev and make it two straight victories.
Abdisalam Kubanychbek, the interim Lightweight champion, will face Kamil Magomedov in the main event of BRAVE CF 69 in an attempt to unify the 155-pound title. On fight night, one of Serbia's top fighters, Aleksandar Ilic, will make his comeback. Another major matchup between two of Europe's brightest emerging stars, Yannis Ghemmouri of France and Borislav Nikolic, will take place at a Catchweight of 64 kg.
The first-ever BRAVE International Combat Week outside of Bahrain will be headlined by the professional event produced by BRAVE CF in collaboration with the Serbian MMA Federation. The largest IMMAF World Championships to date are anticipated to take place between February 11 and February 18 as part of the BRAVE Serbia International Combat Week, which is predicted to grow to be the largest combat sports festival in Europe.
BRAVE CF 69 fight card (so far):
What are your thoughts on the fight card? Let us know in the comments below.